GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turning Point Therapeutics Inc (NAS:TPTX) » Definitions » ROE %

Turning Point Therapeutics (Turning Point Therapeutics) ROE % : -58.46% (As of Jun. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Turning Point Therapeutics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Turning Point Therapeutics's annualized net income for the quarter that ended in Jun. 2022 was $-492.35 Mil. Turning Point Therapeutics's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $842.18 Mil. Therefore, Turning Point Therapeutics's annualized ROE % for the quarter that ended in Jun. 2022 was -58.46%.

The historical rank and industry rank for Turning Point Therapeutics's ROE % or its related term are showing as below:

TPTX' s ROE % Range Over the Past 10 Years
Min: -40.53   Med: -22.92   Max: -20.77
Current: -36.23

During the past 5 years, Turning Point Therapeutics's highest ROE % was -20.77%. The lowest was -40.53%. And the median was -22.92%.

TPTX's ROE % is not ranked
in the Biotechnology industry.
Industry Median: -44.015 vs TPTX: -36.23

Turning Point Therapeutics ROE % Historical Data

The historical data trend for Turning Point Therapeutics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics ROE % Chart

Turning Point Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
- - -40.53 -20.77 -22.92

Turning Point Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.76 -25.45 -31.83 -32.27 -58.46

Competitive Comparison of Turning Point Therapeutics's ROE %

For the Biotechnology subindustry, Turning Point Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turning Point Therapeutics's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turning Point Therapeutics's ROE % distribution charts can be found below:

* The bar in red indicates where Turning Point Therapeutics's ROE % falls into.



Turning Point Therapeutics ROE % Calculation

Turning Point Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=-236.551/( (1109.898+954.425)/ 2 )
=-236.551/1032.1615
=-22.92 %

Turning Point Therapeutics's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as

ROE %=Net Income (Q: Jun. 2022 )/( (Total Stockholders Equity (Q: Mar. 2022 )+Total Stockholders Equity (Q: Jun. 2022 ))/ count )
=-492.352/( (891.347+793.022)/ 2 )
=-492.352/842.1845
=-58.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2022) net income data. ROE % is displayed in the 30-year financial page.


Turning Point Therapeutics  (NAS:TPTX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=-492.352/842.1845
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-492.352 / 0.476)*(0.476 / 891.0605)*(891.0605 / 842.1845)
=Net Margin %*Asset Turnover*Equity Multiplier
=-103435.29 %*0.0005*1.058
=ROA %*Equity Multiplier
=-51.72 %*1.058
=-58.46 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=-492.352/842.1845
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-492.352 / -492.352) * (-492.352 / -497.456) * (-497.456 / 0.476) * (0.476 / 891.0605) * (891.0605 / 842.1845)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9897 * -104507.56 % * 0.0005 * 1.058
=-58.46 %

Note: The net income data used here is four times the quarterly (Jun. 2022) net income data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Turning Point Therapeutics ROE % Related Terms

Thank you for viewing the detailed overview of Turning Point Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Turning Point Therapeutics (Turning Point Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Executives
Paolo Tombesi officer: EVP & Chief Financial Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Steve M Sabus officer: SVP & Chief Commercial Officer 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Brian Sun officer: SVP & General Counsel C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Mohammad Hirmand officer: EVP and Chief Medical Officer C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Athena Countouriotis director, officer: President & CEO C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Siegfried Reich officer: EVP & Chief Scientific Officer 10505 ROSELLE STREET SAN DIEGO CA 92121
Andrew John Partridge officer: EVP & Chief Commercial Officer C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109
Annette North officer: EVP, General Counsel & Secty. C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Van Hoose Kyri K. officer: Principal Accounting Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Brian Lee Baker officer: VP of Finance and Admin. C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Yi Larson officer: EVP & Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Jingrong Jean Cui director, 10 percent owner, officer: Chief Scientific Officer C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428

Turning Point Therapeutics (Turning Point Therapeutics) Headlines